EU Supports Microbiome R&D Via Enterome

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

France's leading microbiome company, Enterome, has raised €32m in a series D financing and secured a €40m loan facility from the European Investment Bank to advance a small molecule and a potential cancer vaccine approach into early-stage clinical studies.

Coins
• Source: Shutterstock.

Research into the microbiome has attracted the attention of the European Investment Bank (EIB), which has granted Paris, France-based Enterome Bioscience SA a €40m ($48m) loan facility to accompany the company's Jan. 4 announced fundraising of €32m ($38.5m) in a Series D financing, that saw the Italy-based VC, Principia SGR and Bristol-Myers Squibb Co. join current Enterome investors in the round.

The EU's EIB invests strategically in European companies it believes are developing new ways of treating patients, and the microbiome...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.